CDMO Momentum Lindy's recent engagement with Lifecore to provide CDMO services for streamlining formulation and scaling microglassification indicates external demand and production readiness. This signals strong sales potential to partner with biotech and pharma companies seeking formulation development, scale-up, and commercial manufacturing for stable protein particles and high-concentration suspensions.

High Dose Subcutaneous Lindy's platform enables high-dose protein suspensions suitable for subcutaneous delivery, which can reduce administration costs and improve patient comfort and compliance. Use this to target developers of monoclonal antibodies and biologics looking to enable convenient, scalable subcutaneous formats.

Long Term Stability Microglassification yields dense, stable protein particles optimized for long-term storage, addressing cold-chain and supply chain challenges. Market opportunities exist with customers needing robust stability for global distribution and extended shelf-life formulations.

Inhaled Biologics The dry powder pulmonary delivery angle opens doors to collaborations with respiratory and inhaled biologics developers seeking alternative delivery routes. Position Lindy as a partner for formulation, stability, and integration into inhalation devices.

Growth and Capacity Recent financing activity and a growth trajectory suggest Lindy is expanding capabilities; this can align with buyers needing additional process development, analytical services, or supply commitments as pipelines mature. Consider outreach to biotech startups and mid-stage companies planning late-stage development and commercial-scale manufacturing.